KHRN:CC - Shares Jump After Colombia Includes Cannabis Products On List of Mandatory Insurance-Covered Medications

The benefits of %MedicalCannabis are numerous and this company is on the ground floor to benefit after Colombia is including the product on its list of mandatory insurance-covered medications.

%KhironLifeSciences () () announced in its press release that as of the new year, plant-based medical cannabis products will be included in Colombia’s the list of mandatory insurance-covered medications. Chiron also signed a first-of-its-kind medical cannabis contract with one of Colombia’s largest insurance companies.

Beginning on January 1, 2023, every insurance provider in Colombia , is mandated to cover the costs of medical cannabis prescriptions for patients. During the first half of 2022, insurance-covered prescriptions represented more than 90% of Khiron´s cannabis sales in Colombia. With a patient base of more than 25,000 patients, the firm will immediately resume filling insurance-covered prescriptions through its Zerenia clinic network.

Canadian shares of Khiron were trading up sharply at $0.08 in morning trade.